DGAP-News

Evotec to report First Quarter 2016 Results on 10 May 2016

DGAP-News: Evotec AG / Key word(s): Miscellaneous
Evotec to report First Quarter 2016 Results on 10 May 2016

03.05.2016 / 09:55
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Hamburg, Germany - 03 May 2016: Evotec AG (Frankfurt Stock Exchange: EVT,
TecDAX, ISIN: DE0005664809) will report its financial results for the first
quarter of 2016 on Tuesday, 10 May 2016.

The Company is going to hold a conference call to discuss the results as
well as to provide an update on its performance. The conference will be
held in English.


Conference call details

Date: Tuesday, 10 May 2016
Time: 02.00 pm CEST (01.00 pm BST/08.00 am EDT)

From Germany: [phone]
From UK: [phone]
From USA: [phone]
From France: [phone]
Access Code: 37969784#

A simultaneous slide presentation for participants dialling in via phone is
available at http://www.audio-webcast.com/, password: evotec0516.


Webcast details

To join the audio webcast and to access the presentation slides you will
find a link on our home page www.evotec.com shortly before the event.

A replay of the conference call will be available for 24 hours and can be
accessed in Europe by dialling [phone] (Germany) or +44 20
3426 2807 (UK) and in the US by dialling [phone]. The access code
is 654573#. The on-demand version of the webcast will be available on our
website:
http://www.evotec.com/article/en/Investors/Finance/Financial-Reports-2013-
2015/188/6/26.


ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient advocacy
groups and venture capitalists. We operate worldwide providing the highest
quality stand-alone and integrated drug discovery solutions, covering all
activities from target-to-clinic to meet the industry's need for innovation
and efficiency in drug discovery (EVT Execute).The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, diabetes and
complications of diabetes, pain and inflammation, oncology and infectious
diseases. On this basis, Evotec has built a broad and deep pipeline of more
than 70 partnered product opportunities at clinical, pre-clinical and
discovery stages (EVT Innovate). Evotec has established multiple long-term
discovery alliances with partners including Bayer, CHDI or UCB and
development partnerships with e.g. Janssen Pharmaceuticals in the field of
Alzheimer's disease, with MedImmune and Sanofi in the field of diabetes,
with Pfizer in the field of tissue fibrosis and with Second Genome in the
field of inflammatory diseases. For additional information please go to
www.evotec.com.


FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.

Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, [e-mail]


---------------------------------------------------------------------------

03.05.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------


Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: [phone]
Fax: [phone]
E-mail: [e-mail]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart; Terminbörse EUREX


End of News DGAP News Service
---------------------------------------------------------------------------

460119 03.05.2016